PMID- 15536194
OWN - NLM
STAT- MEDLINE
DCOM- 20050401
LR  - 20171116
IS  - 1066-5099 (Print)
IS  - 1066-5099 (Linking)
VI  - 22
IP  - 6
DP  - 2004
TI  - CD45 congenic bone marrow transplantation: evidence for T cell-mediated immunity.
PG  - 1039-48
AB  - CD45 congenic mice have been used to study stem cell engraftment in the absence 
      of alloreactivity. Recently, impaired engraftment was reported in this model and 
      attributed to weak immune reactivity. We have confirmed that there is indeed 
      low-level reactivity mediated by CD8(+) cells and alpha beta-TCR(+) T cells. B6 
      (CD45.2) recipients were conditioned with total body irradiation (TBI) and 
      transplanted with increasing doses of B6 (CD45.1) bone marrow cells (BMCs). 
      Although chimerism was present at 1 month in all recipients, durable engraftment 
      did not occur with <150 cGy of TBI, emphasizing the importance of long-term 
      follow-up in evaluating nonmyeloablative conditioning approaches. A single dose 
      of cyclophosphamide on day 2 also significantly enhanced engraftment. When B6 TCR 
      beta(-/-), TCR delta(-/-), or TCR beta(-/-)/delta(-/-) (CD45.2) mice were 
      transplanted with CD45.1 bone marrow, significantly enhanced engraftment occurred 
      in recipients lacking alpha beta-TCR(+) T cells (p < .00005). Similarly, removal 
      of alpha beta-TCR(+) host T cells in wild-type recipients resulted in enhanced 
      engraftment. Engraftment was also significantly increased in CD8(-/-) and 
      CD4(-/-)/8(-/-) recipients (p < .0005). Taken together, these results demonstrate 
      that alpha beta-TCR(+) and CD8(+) T cells play a critical role in regulating 
      engraftment of CD45 congenic marrow and suggest that these cells are the main 
      effector cells in low-level alloreactivity to the CD45 disparity.
FAU - Xu, Hong
AU  - Xu H
AD  - Institute for Cellular Therapeutics, University of Louisville, 570 South Preston 
      Street, Louisville, Kentucky 40202-1760, USA.
FAU - Exner, Beate G
AU  - Exner BG
FAU - Chilton, Paula M
AU  - Chilton PM
FAU - Schanie, Carrie
AU  - Schanie C
FAU - Ildstad, Suzanne T
AU  - Ildstad ST
LA  - eng
GR  - DK52294/DK/NIDDK NIH HHS/United States
GR  - R01 HL63442-01A2/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD4 Antigens)
RN  - 0 (CD8 Antigens)
RN  - 0 (Protein Synthesis Inhibitors)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/chemistry
MH  - Bone Marrow Cells/cytology
MH  - Bone Marrow Transplantation/*methods
MH  - CD4 Antigens/biosynthesis
MH  - CD8 Antigens/biosynthesis
MH  - Cell Lineage
MH  - Cyclophosphamide/pharmacology
MH  - Dose-Response Relationship, Radiation
MH  - Flow Cytometry
MH  - Killer Cells, Natural/cytology
MH  - Leukocyte Common Antigens/*biosynthesis
MH  - Lymphocytes/cytology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Phenotype
MH  - Protein Synthesis Inhibitors/pharmacology
MH  - T-Lymphocytes/*cytology/immunology
MH  - Time Factors
MH  - Transplantation Conditioning/methods
EDAT- 2004/11/13 09:00
MHDA- 2005/04/02 09:00
CRDT- 2004/11/13 09:00
PHST- 2004/11/13 09:00 [pubmed]
PHST- 2005/04/02 09:00 [medline]
PHST- 2004/11/13 09:00 [entrez]
AID - 22/6/1039 [pii]
AID - 10.1634/stemcells.22-6-1039 [doi]
PST - ppublish
SO  - Stem Cells. 2004;22(6):1039-48. doi: 10.1634/stemcells.22-6-1039.